F9

Alienware Unleashes the Ultimate AMD Advantage Laptop and Industry-First 480Hz Display Technology

Retrieved on: 
Tuesday, July 19, 2022
Obsidian, Shift, Radeon, CAD, UHD, G15, View, GB, Technology, Dell G Series, Dell, GDDR6, F9, FreeSync, Video, AMD, Life, 30 for 30, Alienware, GPU, NVIDIA, G16, R2, R5, Industry, APU, Multimedia, Graphics, FHD, USD, MUX, Partnership, RGB, Cryptocurrency, Video game console, Video game

It claims the throne as the world's most powerful 17" AMD Advantage laptop, delivering truly remarkable performance.

Key Points: 
  • It claims the throne as the world's most powerful 17" AMD Advantage laptop, delivering truly remarkable performance.
  • The m17 R5 is forged from a partnership with AMD that features AMD Ryzen 6000 series processors, AMD Radeon RX 6000 series graphics, and new AMD Smart Technologies.
  • Now available with Alienware m17 R5 and Alienware x17 R2 gaming laptops, gamers will make first contact with a brand-new display technology.
  • ii AMD Smart Access Graphics is only available when selecting the UHD 120Hz display option and AMD Radeon graphics.

Propeller Aero and Quantum-Systems Partner to Provide PPK Support for Trinity F90+ Drone in a Win for Large Site Surveying

Retrieved on: 
Tuesday, June 14, 2022
Aircraft, F90, Quantum-Systems, Southampton, Mining, Gesellschaft mit beschränkter Haftung, PPK, F9, AI, CEO, Partnership, Trinity, Solution, Multimedia, Intelligence, Stratus, EVTOL, Acquisition, Trimble, Industry, Efficiency, Propeller, Unmanned aircraft system simulation, Unmanned aerial vehicle, Surveying, Risk management

DENVER, June 14, 2022 /PRNewswire/ --  Propeller Aero, the drone data visualization and analytics platform, and Quantum-Systems, the Unmanned Aircraft Systems developer, today announced their joint effort to include compatibility of Propeller's site surveying and 3D mapping software with Quantum-Systems' Trinity F90+ drone.

Key Points: 
  • Propeller's Post-Processed Kinematic solution (PPK) enables seamless surveying and 3D mapping of worksites across the construction, mining and earthworks industries.
  • "The drone industry has progressed a lot over the last couple of years, along with customer expectations," notes Florian Seibel, Co-founder and CEO of Quantum-Systems.
  • With the full Trimble Stratus solution completed with Trinity F90+, customers can proactively finish their projects from end to end."
  • Quantum-Systems was founded in 2015 and is headquartered at Special Airport Oberpfaffenhofen, 20 km west of Munich.

European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B

Retrieved on: 
Monday, March 28, 2022
People, Haemophilia B, Cell, Marketing, Factor IX, Lance, EEA, MAA, DNA, Bleeding, Public health, European Medicines Agency, AAV, Adult, European Economic Area, Coagulopathy, Observation, Patient, CSL, Achievement, CSL Behring, Pain, Joint, FIX, Safety, Review, CSL Limited, F9, ABR, Muscle, Padua, Haemophilia, EMA, Union, Phenotype, Swelling, Protein, Pharmaceutical industry, Birth control, Vaccine, EU

MARBURG, Germany, March 28, 2022 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for etranacogene dezaparvovec (EtranaDez) under its accelerated assessment procedure. Etranacogene dezaparvovec is an investigational adeno-associated virus five (AAV5)-based gene therapy administered as a one-time treatment for hemophilia B patients with a severe bleeding phenotype. If approved, etranacogene dezaparvovec will provide people living with hemophilia B in the European Union (EU) and European Economic Area (EEA) with the first-ever gene therapy treatment option that significantly reduces the rate of annual bleeds after a single infusion. Accelerated assessment potentially reduces the timeline once the MAA is accepted for review and is provided for a medicinal product when the therapy is expected to be of major public health interest, particularly pertaining to therapeutic innovation.

Key Points: 
  • Etranacogene dezaparvovec is an investigational adeno-associated virus five (AAV5)-based gene therapy administered as a one-time treatment for hemophilia B patients with a severe bleeding phenotype.
  • If approved, etranacogene dezaparvovecwill providepeople living with hemophilia B in the European Union (EU) and European Economic Area (EEA) with the first-ever gene therapy treatment option that significantly reduces the rate of annual bleeds after a single infusion.
  • The MAA is supported by positive findings from the pivotal HOPE-B trial, the largest gene therapy trial in hemophilia B to date.
  • Gene therapy has the potential to make a functional cure possible in hemophilia B. Gene therapy achieves this with modified non-infectious viruses called "vectors" that can enter certain cells.

European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B

Retrieved on: 
Monday, March 28, 2022
People, Haemophilia B, Cell, Marketing, Factor IX, Lance, EEA, MAA, DNA, Bleeding, Public health, European Medicines Agency, AAV, Adult, European Economic Area, Coagulopathy, Observation, Patient, CSL, Achievement, CSL Behring, Pain, Joint, FIX, Safety, Review, CSL Limited, F9, ABR, Muscle, Padua, Haemophilia, EMA, Union, Phenotype, Swelling, Protein, Pharmaceutical industry, Birth control, Vaccine, EU

MARBURG, Germany, March 28, 2022 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for etranacogene dezaparvovec (EtranaDez) under its accelerated assessment procedure. Etranacogene dezaparvovec is an investigational adeno-associated virus five (AAV5)-based gene therapy administered as a one-time treatment for hemophilia B patients with a severe bleeding phenotype. If approved, etranacogene dezaparvovec will provide people living with hemophilia B in the European Union (EU) and European Economic Area (EEA) with the first-ever gene therapy treatment option that significantly reduces the rate of annual bleeds after a single infusion. Accelerated assessment potentially reduces the timeline once the MAA is accepted for review and is provided for a medicinal product when the therapy is expected to be of major public health interest, particularly pertaining to therapeutic innovation.

Key Points: 
  • Etranacogene dezaparvovec is an investigational adeno-associated virus five (AAV5)-based gene therapy administered as a one-time treatment for hemophilia B patients with a severe bleeding phenotype.
  • If approved, etranacogene dezaparvovecwill providepeople living with hemophilia B in the European Union (EU) and European Economic Area (EEA) with the first-ever gene therapy treatment option that significantly reduces the rate of annual bleeds after a single infusion.
  • The MAA is supported by positive findings from the pivotal HOPE-B trial, the largest gene therapy trial in hemophilia B to date.
  • Gene therapy has the potential to make a functional cure possible in hemophilia B. Gene therapy achieves this with modified non-infectious viruses called "vectors" that can enter certain cells.

Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B - Data Presented at EAHAD 2022

Retrieved on: 
Friday, February 4, 2022
CSL Behring, Factor IX, CSL, Clinical trial, ABR, Bleeding, Haemophilia, Male, F9, Annual general meeting, Teaching hospital, FIX, Haemophilia B, Disease, Association, Department, European Association for the Study of the Liver, Pharmaceutical industry

The final data, from the largest gene therapy study in hemophilia B, were presented as part of the latest clinical trial results session at the European Association of Haemophilia and Allied Disorders (EAHAD) 2022 Annual Meeting.

Key Points: 
  • The final data, from the largest gene therapy study in hemophilia B, were presented as part of the latest clinical trial results session at the European Association of Haemophilia and Allied Disorders (EAHAD) 2022 Annual Meeting.
  • "Nearly all patients treated with gene therapy in this study were able to discontinue use of prophylaxis.
  • The pivotal Phase III HOPE-B trial is a multinational, open-label, single-arm study to evaluate the safety and efficacy ofetranacogene dezaparvovec.
  • Gene therapy has the potential to make a functional cure possible in hemophilia B. Gene therapy achieves this with modified non-infectious viruses called "vectors" that can enter certain cells.

Nonprofit Accounting Software Consulting Firm Launches Power Cloud Reporting

Retrieved on: 
Thursday, August 5, 2021
Cloud, Blackbaud, Income, F9, Consolidation, Security, Multimedia, Time, Organization, Solution, Video game console, Bookkeeping, Online shopping

RALEIGH, N.C., Aug. 5, 2021 /PRNewswire/ -- Power Cloud Reporting is the latest software launch from Capital Business Solutions, a training and consulting firm specializing in nonprofit accounting software .

Key Points: 
  • RALEIGH, N.C., Aug. 5, 2021 /PRNewswire/ -- Power Cloud Reporting is the latest software launch from Capital Business Solutions, a training and consulting firm specializing in nonprofit accounting software .
  • In addition to providing Financial Edge NXT consulting that includes training, configuration, and ongoing consultation services, they also build complementary software applications to expand the capabilities and end user benefits of Blackbaud's software offerings.
  • Power Cloud Reporting was specifically built for Financial Edge NXT and current F9 users as it integrates the functionality and familiarity of Excel to create reports and formats not available in the existing Financial Edge NXT platform.
  • - Bob Schilling, Vice President Sales
    To learn more about Power Cloud's Reporting, register for a free informational webinar by visiting their website designed by internet marketing agency , TheeDigital.

AMC Theatres Races to a Post-Reopening Record Weekend With More Than 2 Million U.S. Guests and the Biggest U.S. Movie Opening at the Box Office Since 2019

Retrieved on: 
Monday, June 28, 2021
General Entertainment, Entertainment, Film & Motion Pictures, Films, Creative works, English-language films, IMAX films, F9, It

Some 2 million people watched movies at AMCs United States theatre locations between Thursday, June 24 and Sunday, June 27.

Key Points: 
  • Some 2 million people watched movies at AMCs United States theatre locations between Thursday, June 24 and Sunday, June 27.
  • These are the biggest numbers recorded by AMC in the U.S. since closing its theaters in March of 2020 due to the coronavirus pandemic.
  • F9: THE FAST SAGA opened to an estimated $70 million for its opening weekend in the United States, shattering the previous post-reopening record.
  • In fact, the $70 million is the biggest opening weekend for any movie in the U.S. since late in 2019.

IMAX Races to Top Domestic Opening of Pandemic Era With $5.5 Million Debut of "F9"

Retrieved on: 
Sunday, June 27, 2021
Films, Creative works, IMAX films, English-language films, 3D imaging, Film formats, IMAX, Spectre, F9

NEW YORK, June 27, 2021 /PRNewswire/ --IMAX (NYSE: IMAX) continued to set the pace for summer blockbuster season as it delivered a $5.5 million domestic opening for Universal's "F9" driving IMAX to its biggest weekend at the domestic box office of the pandemic era.

Key Points: 
  • NEW YORK, June 27, 2021 /PRNewswire/ --IMAX (NYSE: IMAX) continued to set the pace for summer blockbuster season as it delivered a $5.5 million domestic opening for Universal's "F9" driving IMAX to its biggest weekend at the domestic box office of the pandemic era.
  • IMAX has now earned $30 million at the global box office with "F9," which began its international rollout last month with a strong debut in Asia and the Middle East.
  • "F9" will continue to run in domestic IMAX theaters through next weekend, and open in additional markets in Europe in the coming weeks.
  • Disney's "Black Widow" makes its long-awaited debut in the IMAX domestic network on July 9.

UNIVERSAL PICTURES THANKS FRONTLINE HOSPITAL WORKERS WITH INVITATIONS TO THE LOS ANGELES PREMIERE OF "F9" AND OFFERS FREE F9 TICKETS TO HOSPITAL WORKERS IN MORE THAN 10 CITIES ACROSS THE U.S.

Retrieved on: 
Wednesday, June 16, 2021
Entertainment, Cinemark Theatres, Event venues, Harkins Theatres, AMC Theatres, Movie theater, F9, Films

on June 18, and will offer free F9 tickets to hospital workers in 11 major U.S. cities.

Key Points: 
  • on June 18, and will offer free F9 tickets to hospital workers in 11 major U.S. cities.
  • For the F9 premiere in Los Angeles on June 18, Universal will invite approximately 200 frontline workers from L.A. area hospitals that were among the hardest-hit during the pandemic to attend the premiere with one guest of their choice.
  • In addition to the premiere, Universal, AMC Theatres, Regal, Cinemark, Harkins Theatres and Marcus Theatres/Movie Tavern will be offering free F9 tickets to frontline hospital works in 11 major U.S. cities.
  • In select cities, hospital workers may also be invited to free screenings of the film.

To Celebrate The Arrival Of "F9" In Theaters June 25 Universal Pictures Announces "Fast Fridays" Eight Weeks Of Free Nationwide Screenings Of Every Previous "Fast And Furious" Film

Retrieved on: 
Friday, April 23, 2021
Films, Cinema of the United States, American film studios, English-language films, Roth/Kirschenbaum Films, Fast & Furious, Original Film, Justin Lin, One Race Films, F9, Universal Pictures

And we cannot wait to blow everyone\'s minds with the release of F9 on June 25.

Key Points: 
  • And we cannot wait to blow everyone\'s minds with the release of F9 on June 25.
  • Each episode will focus on one movie in the franchise with a Fast cast member from that particular film.
  • This time, that threat will force Dom to confront the sins of his past if he\'s going to save those he loves most.
  • Universal Pictures presents an Original Film/One Race Films/Perfect Storm production in association with Roth/Kirschenbaum Films, a Justin Lin film.